Mark is Head of CNS & Pain and an expert in neurology, pain and critical care medicine. He has over 27 years’ experience in the industry and previously held senior medical positions at Cephalon, Novo Nordisk and Archimedes Pharma.
With a background in general practice, aviation and sports medicine, Mark entered the pharmaceutical industry in 1992 and spent six years working in contract research organisations (Til Occam, Quintiles) gaining experience in the design and implementation of clinical development programmes across many therapeutic areas.
From there, Mark moved into positions such as European Medical Director at Cephalon, Head of Medical Partnership at Novo Nordisk and Group Medical Director at Archimedes Pharma, where he participated in and then led teams engaged in the development and approval of products focussed particularly in CNS / neurology, pain, immunology and critical care across the major markets. He was also responsible for medical support to their commercialisation through the development of in-house and contracted services such as medical liaison, medical information and pharmacovigilance.
Mark has broad experience in translational/early- and late-phase clinical development, medical affairs, and general programme and departmental management in companies both large and small. This, allied to his therapeutic area expertise, means he can make a flexible and hands-on contribution to the activities of a wide variety of organisations.